ReviewBiomedicines2024
The Re-Emergence of Mpox: Old Illness, Modern Challenges.
Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point.Molecular diversity · 2026Review
- A Global Health Alert on the Re-Emergence of Mpox a Viral Zoonotic Illness Its Prevention and Management: A Narrative Review.Health science reports · 2026Article
- Mpox and the one health approach.Dialogues in health · 2026Review
- Pre-exposure vaccination in the high-risk population is crucial in controlling mpox resurgence in Canada.BMC infectious diseases · 2025Article
- Assessment of Knowledge, Attitude, and Practice Towards the Prevention of Monkeypox Among People of Bangladesh With at Least Primary Education: A Cross-Sectional Study.Health science reports · 2025Article
- Mpox: Global epidemic situation and countermeasures.Virulence · 2025Review
- Impact of open markets on zoonotic threats and antimicrobial resistance: A One Health concern.One health (Amsterdam, Netherlands) · 2025Review
- Comparative analysis of Mpox clades: epidemiology, transmission dynamics, and detection strategies.BMC infectious diseases · 2025Review
- Neurological complications of Orthopoxvirus infections: neurotropism and neurovirulence.Brain : a journal of neurology · 2025Review
- Mpox-XDE: an ensemble model utilizing deep CNN and explainable AI for monkeypox detection and classification.BMC infectious diseases · 2025Article
- Article
- Personalized immunization against Mpox Clades I and Ib: Strategies to combat the emerging epidemic.Infectious medicine · 2025Review
- A review of epidemiology, diagnosis, and management of Mpox: The role of One Health.Global health & medicine · 2025Review
- Article
- Current status of next-generation vaccines against mpox virus: a scoping review.Frontiers in pharmacology · 2025Review
- Mpox: An emerging or re-emerging infection with a potential colossal burden on healthcare globally.African journal of laboratory medicine · 2025Review
- Vulnerability characteristics and adaptation strategies of public health systems in different regions of China.Frontiers in public health · 2025Review
- Disparity in Mpox awareness and vaccine hesitancy: a cross-sectional study of 3,483 university students in Northwest China.Frontiers in public health · 2025Article
- The evolving mpox threat (2022-2024): clade dynamics, immune evasion, and escalating global health challenges.Frontiers in cellular and infection microbiology · 2025Review
- Time series modelling and forecasting of Monkeypox outbreak trends Africa's in most affected countries.New microbes and new infections · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Mpox virus (MPXV) is known to cause zoonotic disease in humans. The virus belongs to the genus Orthopoxvirus, of the family Poxviridae, and was first reported in monkeys in 1959 in Denmark and in humans in 1970 in the Congo. MPXV first appeared in the U.S. in 2003, re-emerged in 2017, and spread globally within a few years. Wild African rodents are thought to be the reservoir of MPXV. The exotic trade of animals and international travel can contribute to the spread of the Mpox virus. A phylogenetic analysis of MPXV revealed two distinct clades (Central African clade and West African clade). The smallpox vaccine shows cross-protection against MPXV infections in humans. Those who have not previously been exposed to Orthopoxvirus infections are more vulnerable to MPXV infections. Clinical manifestations in humans include fever, muscle pain, headache, and vesicle formation on the skin of infected individuals. Pathognomonic lesions include ballooning degenerations with Guarnieri-like inclusions in vesicular epithelial cells. Alterations in viral genome through genetic mutations might favor the re-emergence of a version of MPXV with enhanced virulence. As of November 2023, 92,783 cases and 171 deaths have been reported in 116 countries, representing a global public health concern. Here, we provide insights on the re-emergence of MPXV in humans. This review covers the origin, emergence, re-emergence, transmission, pathology, diagnosis, control measures, and immunomodulation of the virus, as well as clinical manifestations. Concerted efforts of health professionals and scientists are needed to prevent the disease and stop its transmission in vulnerable populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.